Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Molecular profiling enabled targeted treatment that significantly improved survival in advanced cholangiocarcinoma. Learn ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and ...

The robot completed 88 per cent of the steps on its first attempt, followed by real-time adjustments and corrections to ...

A new study published in the journal of Nature Scientific Reports showed that metabolic dysfunction-associated steatotic ...

Patients with primary biliary cholangitis and moderate-to-severe pruritus who received seladelpar over 6 months experienced a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing ...

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial (NCT02912949), evaluating zenocutuzumab in patients ...